Why partner with Recordati

Recordati is a global pharmaceutical group with more than 4,300 employees and has a direct presence in all key geographies.

Recordati is a partner of choice due to its unique structure, bringing treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. We are continually growing, with a focus on developing new specialties, new treatments and investing in medical innovations that bring a brighter future to patients across the world. Partnerships are a core component of Recordati’s successful history. The company has developed a long-standing track record and commitment to partnering and we have the focus to treat each product as if it were our own.

Strong capabilities
& global reach

  • Fully integrated company with successful track record in developing, registering, manufacturing and commercialising medicinal products

  • Global footprint with direct presence in more than 30 countries and partnerships in remaining markets

Focus

  • A “local brilliance” commercial approach to each and every market, ensuring growth opportunities are maximised

  • Growth driven by focus on few strategic products that add value to patients, payers and physicians

  • We treat each partnered product as if it were our own

Business development
track record

  • Creative and flexible deal structures to share value with partners

  • Long-lasting strategic partnerships

  • More than 35 transactions completed in the last 15 years

Specialty & Primary Care

  • Recordati Specialty and Primary Care has significant scope and scale with cost-effective and competitive commercial capabilities in every market in which we operate.

  • We are the go-to partner for innovative treatments in our core therapeutic areas as well as for promotionally sensitive established and marketed products across multiple therapy areas.

  • We invest and focus on local and regional flagship brands in consumer healthcare, combining digital innovation and clinical advocacy.

Rare Diseases

  • Recordati Rare Diseases has a global footprint with direct commercial presence in major markets.

  • We are the go-to partner for global, regional and local partnerships for innovative rare disease treatments with a particular focus in our core therapeutic areas.

Our Business Development Strategy

We are looking for in-licensing and acquisition opportunities to strengthen our pipeline and portfolio in the following areas:

Rare Diseases

Innovative products from Clinical Proof of Concept programmes to marketed products, in all therapeutic areas and with a particular focus on:

 

  • Rare Endocrinology
  • Rare Metabolism
  • Rare Oncology

Specialty & Primary Care

Innovative products from Phase 2b clinical stage to marketed products in:

 

  • Cardio-metabolism

  • Urology/Uro-Oncology

  • Gastrointestinal

Established and marketed products across any therapeutic area

Consumer Healthcare

Well established and marketed CHC products mainly in categories such as:

  • Digestive Health

  • Women’s Health & Intimate Care

  • Respiratory Health

Share your proposed Partnership

If your product can make a difference to patients and fits within our Business Development Strategy, we would like to hear from you.

Email:

Upcoming Partnering Events

November 14, 2023
-
November 15, 2023
London (UK)
Jefferies – London Healthcare Conference
View Event
November 9, 2023
-
22nd January, 2023
Virtual
Deutsch Bank – Roadshow
View Event
November 8, 2023
-
22nd January, 2023
Zürich, Geneva
Jefferies – Roadshow
View Event
November 7, 2023
-
22nd January, 2023
Munich, Germany
Board of Directors’ meeting to approve the 2023 first nine months’ results, as additional voluntary financial reporting
View Event
September 26, 2023
-
22nd January, 2023
Virtual
J.P. Morgan – EU Healthcare CEO Conference Calls Series
View Event
September 21, 2023
-
22nd January, 2023
Virtual
Jefferies – “Back to School” CEO fireside chat
View Event

Selected Partnerships

Licensor
Trademark (Rights for)
Therapeutic Area
Eligard®
Uro-oncology
APEIRON Biologics AG
Qarziba® (Worldwide)
Rare oncology
AVEO Pharmaceuticals, Inc
Fotivda® (Europe, Latin America, Africa, Australia and New Zealand)
Rare oncology
The Simple Pharma Company UK Limited
Vitaros®/Virirec® (Selected European Countries and Africa Portuguese-speaking countries)
Urology
Gedeon Richter Plc.
Reagila® (Western Europe, Turkey and selected countries in Africa)
Central Nervous System
Helsinn Healthcare SA.
Ledaga® (Worldwide excluding the USA, Israel, China and other Asian countries)
Onco-dermatology
KISSEI PHARMACEUTICAL CO.,LTD.
Urorec®/Silodyx™/Silosin® (Europe & other selected countries)
Urology
KOWA PHARMACEUTICAL EUROPE CO. LTD
Livazo®/Alipza® (Europe excluding UK and Germany)
Cardiometabolism
PLETHORA SOLUTIONS LIMITED
Fortacin™ (EU, UK and other selected countries)
Urology
Takeda Pharmaceutical Company Limited
Peptazol® (italy)
Gastrointestinal
Amryt Pharma Plc
Juxtapid® (Japan)
Rare metabolism
Shionogi & Co., Ltd
Rizmoic® (Spain, Portugal)
Gastrointestinal
GSK
Avodart® and Combodart®/ Duodart®
Urology

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.